These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1147 related articles for article (PubMed ID: 27289126)

  • 1. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
    Ferrannini E; Mark M; Mayoux E
    Diabetes Care; 2016 Jul; 39(7):1108-14. PubMed ID: 27289126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Mudaliar S; Alloju S; Henry RR
    Diabetes Care; 2016 Jul; 39(7):1115-22. PubMed ID: 27289124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Cardiol; 2017 Jul; 120(1S):S28-S36. PubMed ID: 28606341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
    Abdul-Ghani M; Del Prato S; Chilton R; DeFronzo RA
    Diabetes Care; 2016 May; 39(5):717-25. PubMed ID: 27208375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton RJ
    Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
    Luconi M; Raimondi L; Di Franco A; Mannucci E
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
    Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
    Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.